National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Pulmonary fungal infections are common potentially life-threatening conditions in immuno-compromised patients. Diagnosis represents a challenge due to the non-specific clinical manifestations. Empirical use of anti-fungal drug therapy has been a burden for years due to high cost and drug toxicity. This study was designed to determine the presence of Candida chest infection in immuno-compromised patients in Tanta University Hospitals. A total of 150 patients with chest infection were selected during the period from June 2015 till June 2017. Collected samples were cultured on Sabouraud's Dextrose agar media. Candida isolates were tested using integral system yeast plus (ISYP) for yeast typing and antifungal susceptibility. Out of 150 tested samples, candida was isolated from 44 samples. ISYP showed that The highest prevalence (36.4%) was for Candida albicans, followed by Candida tropicalis (25%), thirdly Candida parapsilosis (15.9%), then Candida krusei (11.4%), followed by Candida famata, Candida stellatoidea and Candida zylanooides with percentage as (4.5, 4.5 and 2.3%) respectively. Each candida species has different antifungal sensitivity patterns. It is concluded that Candida albicans, Candida tropicalis and Candida parapsilosis were the predominant Candida species causing chest infections in immuno-compromised patients. Further studies must be done to test the sensitivity and accuracy of ISYP.
Citations |
 |
 |
 |
 |
